Stocks Charging Up for Historic Highs: Kinross Gold Corporation (NYSE:KGC), Uranium Energy Corp. (NYSE:UEC)

Kinross Gold Corporation (NYSE:KGC) kept active in under and overvalue discussion, KGC holds price to book ratio of 0.98 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation.

Kinross Gold Corporation (KGC) will release its fourth quarter and 2016 full-year financial statements and operating results on Wednesday, February 15, 2017, after market close. The Company will also provide its full-year 2017 guidance, mineral reserve and mineral resource statement as of December 31, 2016, and an exploration update. Kinross will hold a conference call and audio webcast on Thursday, February 16, 2017 at 8 a.m. ET to present the results, followed by a question-and-answer session.

Fundament/ News Factor in Focus

Taking look on ratio analysis, KGC has forward price to earnings ratio of 27.62.  The co is presenting price to cash flow as 5.74 and while calculating price to free cash flow it concluded at 10.56, the low single digit may indicate stock is undervalued and vice versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower.

The firm has price volatility of 4.27% for a week and 4.81% for a month. Its beta stands at 0.31 times. Narrow down four to firm performance, its weekly performance was 2.43% and monthly performance was 4.98%.

Uranium Energy Corp. (NYSE:UEC) runs in leading trade, it an ascending 12.16% to traded at $1.66. UEC attains analyst recommendation of 1.70 on scale of 1-5 with week’s performance of 27.69%.

To find out the technical position of UEC, it holds price to book ratio of 7.22 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach.  EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 35.40%, and looking further price to next year’s EPS is -9.10%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *